dashboardMD Partners with Henry Schein’s MicroMD to Provide Integrated Healthcare Analytics and Turnkey Business Intelligence Reporting

June 03, 2013 -- dashboardMD, a leading provider of business intelligence reporting solutions for healthcare, is further expanding its healthcare dashboards and intelligent reporting solutions through a strategic partnership with Henry Schein MicroMD®, a provider of proven and cost-effective practice management (PM) and electronic medical records (EMR) systems.

MicroMD PM is a full-featured practice management system that offers advanced scheduling, patient registration, billing, claims management reporting and more. With dashboardMD’s turnkey performance management model, users of MicroMD will gain insightful and actionable intelligence while saving a lot of time by eliminating manual administrative reporting. In addition, users can look forward to quickly addressing more advanced one-off report requests with the powerful ad hoc tools.

“We were pleased that dashboardMD was able to make its solution available to MicroMD clients,” remarked Don Quackenbush, Director of Product Management for Henry Schein MicroMD. “dashboardMD adds value to MicroMD by complementing our existing reporting and offering advanced reporting concepts, KPIs and insightful views into the data.”

The simple and easy-to-use reporting environment of dashboardMD does not require practices and providers utilizing MicroMD to have programming knowledge. Due to its intuitive design, it provides information at users’ fingertips in a graphical, dashboard view, which allows them to even better analyze the performance of their practice.

According to Jose Valero, President and CEO of dashboardMD, “dashboardMD is a perfect complement to MicroMD’s excellent reporting capabilities and fits nicely as an additional administrative reporting layer. With our seamless integration, MicroMD customers can now quickly and easily utilize the business performance management and analytics to implement new strategies, evaluate their effectiveness with benchmarking and promote best practices.”

About MicroMD
The Henry Schein MicroMD brand of practice solutions encompasses simple yet powerful electronic medical records and practice management software that help facilitate the delivery of superior patient care; automate incentive and quality reporting activities; and streamline operations for today’s busy providers. Full-featured, time-tested and budget-friendly, the MicroMD CCHIT-certified, award-winning software helps small practices, large medical groups, community health centers and billing services accelerate progress towards a paperless environment and health information exchange with minimal disruption and stress. High client retention rates attest to its market-leading presence and client-centric focus. Visit us at http://www.micromd.com or call 1-800-624-8832.

About dashboardMD
dashboardMD (http://www.dashboardMD.com) is a leading provider of Business Intelligence solutions and healthcare analytics for provider organizations. The company’s unique daily processing and turnkey management model completely automates revenue cycle monitoring and analysis. Web-based enterprise reporting tools include Daily Dashboards, Scorecards, Alerts, Ad Hoc and Predictive Analytics. Reports can be pushed via e-mail, exported to Excel/PDF or displayed as interactive dashboard screens with color coded charts, graphs, gauges and tables. Implementation is easy, and the entire service is delivered through a low-risk, Software-as-a-Service business model.            

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.